Takeda to acquire cell therapy company TiGenix

Japan’s Takeda Pharmaceutical Company Ltd has announced plans to acquire the Belgium-based cell therapy company TiGenix NV for €520 million, a company with which it already has a licensing deal for the company’s lead product.

Full text available to subscribers only. Click here for information on subscribing to MedNous.